Fulgent Genetics, Inc. (FLGT)
USD 18.93
(9.2%)
USD 18.93
(9.2%)
| Year | Net Debt | Net Debt Growth |
|---|---|---|
| 2023 | -82.56 Million USD | -40.26% |
| 2022 | -58.86 Million USD | 59.01% |
| 2021 | -143.61 Million USD | -100.65% |
| 2020 | -71.57 Million USD | -670.5% |
| 2019 | -9.28 Million USD | -37.9% |
| 2018 | -6.73 Million USD | -3.79% |
| 2017 | -6.49 Million USD | 17.82% |
| 2016 | -7.89 Million USD | -1514.93% |
| 2015 | -489 Thousand USD | -184.3% |
| 2014 | -172 Thousand USD | 0.0% |
| 2001 | -164.89 Million USD | 0.0% |
| Year | Net Debt | Net Debt Growth |
|---|---|---|
| 2024 Q1 | -41.73 Million USD | 49.45% |
| 2024 Q2 | -51.73 Million USD | -23.95% |
| 2023 Q2 | -53.78 Million USD | -18.05% |
| 2023 Q1 | -45.56 Million USD | 22.6% |
| 2023 Q3 | -81.18 Million USD | -50.94% |
| 2023 Q4 | -82.56 Million USD | -1.7% |
| 2023 FY | -82.56 Million USD | -40.26% |
| 2022 Q1 | -331.98 Million USD | -131.17% |
| 2022 Q4 | -58.86 Million USD | 60.3% |
| 2022 Q2 | -117.98 Million USD | 64.46% |
| 2022 FY | -58.86 Million USD | 59.01% |
| 2022 Q3 | -148.29 Million USD | -25.68% |
| 2021 Q1 | -136.41 Million USD | -90.6% |
| 2021 FY | -143.61 Million USD | -100.65% |
| 2021 Q4 | -143.61 Million USD | 25.19% |
| 2021 Q3 | -191.97 Million USD | -144.61% |
| 2021 Q2 | -78.48 Million USD | 42.47% |
| 2020 Q2 | 433 Thousand USD | 106.44% |
| 2020 Q3 | -50.28 Million USD | -11713.86% |
| 2020 Q4 | -71.57 Million USD | -42.32% |
| 2020 FY | -71.57 Million USD | -670.5% |
| 2020 Q1 | -6.72 Million USD | 27.57% |
| 2019 Q4 | -9.28 Million USD | 47.66% |
| 2019 Q2 | -6.37 Million USD | -165.02% |
| 2019 FY | -9.28 Million USD | -37.9% |
| 2019 Q1 | -2.4 Million USD | 64.27% |
| 2019 Q3 | -17.74 Million USD | -178.21% |
| 2018 Q2 | -3.65 Million USD | 30.72% |
| 2018 Q3 | -8.48 Million USD | -132.32% |
| 2018 FY | -6.73 Million USD | -3.79% |
| 2018 Q1 | -5.27 Million USD | 18.74% |
| 2018 Q4 | -6.73 Million USD | 20.65% |
| 2017 Q4 | -6.49 Million USD | 31.53% |
| 2017 Q2 | -11.47 Million USD | -70.37% |
| 2017 Q1 | -6.73 Million USD | 14.73% |
| 2017 FY | -6.49 Million USD | 17.82% |
| 2017 Q3 | -9.47 Million USD | 17.39% |
| 2016 Q1 | -1.02 Million USD | -109.2% |
| 2016 Q4 | -7.89 Million USD | 3.75% |
| 2016 Q3 | -8.2 Million USD | 48.91% |
| 2016 Q2 | -16.06 Million USD | -1469.89% |
| 2016 FY | -7.89 Million USD | -1514.93% |
| 2015 FY | -489 Thousand USD | -184.3% |
| 2015 Q4 | -489 Thousand USD | 0.0% |
| 2014 FY | -172 Thousand USD | 0.0% |
| 2001 FY | -164.89 Million USD | 0.0% |
| Name | Net Debt | Net Debt Difference |
|---|---|---|
| Aclaris Therapeutics, Inc. | -39.45 Million USD | -109.282% |
| Applied DNA Sciences, Inc. | -5.91 Million USD | -1296.101% |
| Aspira Women's Health Inc. | -331 Thousand USD | -24844.411% |
| Biodesix, Inc. | 34.3 Million USD | 340.668% |
| BioNexus Gene Lab Corp. | -5.79 Million USD | -1324.549% |
| bioAffinity Technologies, Inc. | -1.24 Million USD | -6542.847% |
| bioAffinity Technologies, Inc. | -1.24 Million USD | -6542.847% |
| Bionano Genomics, Inc. | 34.88 Million USD | 336.701% |
| CareDx, Inc | -47.97 Million USD | -72.099% |
| Check-Cap Ltd. | -24.75 Million USD | -233.519% |
| Castle Biosciences, Inc. | -83.53 Million USD | 1.155% |
| DarioHealth Corp. | -7.54 Million USD | -993.879% |
| Exact Sciences Corporation | 1.94 Billion USD | 104.236% |
| Guardant Health, Inc. | 220.22 Million USD | 137.491% |
| ICON Public Limited Company | 3.56 Billion USD | 102.319% |
| IDEXX Laboratories, Inc. | 493.94 Million USD | 116.716% |
| Illumina, Inc. | 1.21 Billion USD | 106.801% |
| Intelligent Bio Solutions Inc. | -5.43 Million USD | -1419.809% |
| iSpecimen Inc. | -2.14 Million USD | -3744.889% |
| Standard BioTools Inc. | 46.5 Million USD | 277.538% |
| MDxHealth SA | 18.88 Million USD | 537.204% |
| 23andMe Holding Co. | -141.37 Million USD | 41.597% |
| Medpace Holdings, Inc. | -103.32 Million USD | 20.093% |
| Myriad Genetics, Inc. | 88.1 Million USD | 193.719% |
| Mainz Biomed B.V. | 349.85 Thousand USD | 23700.063% |
| ENDRA Life Sciences Inc. | -2.43 Million USD | -3284.54% |
| NeoGenomics, Inc. | 269.19 Million USD | 130.672% |
| Neogen Corporation | 735.62 Million USD | 111.224% |
| Inotiv, Inc. | 382.14 Million USD | 121.606% |
| Natera, Inc. | -200.1 Million USD | 58.738% |
| OpGen, Inc. | 11.89 Million USD | 794.306% |
| OPKO Health, Inc. | 230.68 Million USD | 135.792% |
| Psychemedics Corporation | 334 Thousand USD | 24820.359% |
| Prenetics Global Limited | -43.33 Million USD | -90.521% |
| Prenetics Global Limited | -43.33 Million USD | -90.521% |
| Precipio, Inc. | -386 Thousand USD | -21290.155% |
| Personalis, Inc. | -8.02 Million USD | -929.245% |
| RadNet, Inc. | 1.14 Billion USD | 107.189% |
| Sera Prognostics, Inc. | -2.02 Million USD | -3983.383% |
| Sotera Health Company | 2.02 Billion USD | 104.077% |
| Neuronetics, Inc. | 2.79 Million USD | 3051.949% |
| Star Equity Holdings, Inc. | -15.33 Million USD | -438.345% |
| Star Equity Holdings, Inc. | -15.33 Million USD | -438.345% |
| Trinity Biotech plc | 63.73 Million USD | 229.544% |
| T2 Biosystems, Inc. | 33.8 Million USD | 344.213% |
| Twist Bioscience Corporation | -192.4 Million USD | 57.087% |
| Exagen Inc. | -12.77 Million USD | -546.461% |